A few people in the top echelon of the 15 highest paid R&D execs in the US — based on available data from the wave of proxy statements that have been filed so far this year — did better in 2017. But the trend overall was down, by a bit, and way off from the go-go years topped by 2014. Still, no one on this list could be considered hard up for cash.
The list is based on total compensation, including stock awards and options that typically deliver the lion’s share of the value. We're sticking with the US due to reporting requirements that make these numbers public, which is lacking overseas. Ironically, though, the European Big Pharmas have a different — lower — pay scale that typically keep them far behind their better paid US counterparts.
So let’s get started.
1 George Yancopoulos RegeneronPresident and Chief Scientific Officer
2016: $27.8 million
2015: $40.0 million
George Yancopoulos is in a class of R&D execs all on his own. While his compensation package was trimmed to $27.8 million last year, it was still more than double the next name on the list. The reason is that as co-founder of the highly successful company, he’s been moving to parity with CEO Len Schleifer. Yancopoulos also owns a chunk of Regeneron stock that makes him a billionaire —2.9% to be exact, or 3,047,986 shares. worth $1.2 billion on Friday’s close.
To continue reading #2 - #15, please log-in or subscribe now for instant access.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
Get Endpoints News in your inbox
News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.
You're subscribing to Endpoints News
John Carroll, Editor and Co-Founder
We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.